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To the Editor: I read with interest the case of primary
aldosteronism (PA) presented by Chen et al.1 The clinical course,
resolution of hypokalemia and hypertension by right adrena-
lectomy, and the pathological finding, a cortical microadenoma
in the resected adrenal gland, support their diagnosis of
aldosterone-producing adenoma of the right adrenal gland.
However, I would like to comment about a potential pitfall in
the usage of 131I-6-beta-iodomethylnorcholesterol (131I-NP-59)
to detect the origin of aldosterone hypersecretion in PA.
The unilateral uptake of 131I-NP-59 under dexamethasone
suppression in PA could indicate aldosterone hypersecre-
tion from the side with the uptake. However, cases of
false-positive unilateral uptake in hyperplasia and cases of false
negative localizations (bilateral positive, bilateral negative, and
incorrect side-positive) in aldosterone-producing adenoma
have been reported.2,3 Therefore, the 131I-NP-59 uptake would
not properly indicate the side of aldosterone hypersecretion in
some cases of PA. Adrenal vein sampling (AVS) is now
considered the most reliable test for detecting the side of
aldosterone hypersecretion in PA.4 The treatment for PA, either
adrenalectomy or medical treatment with a mineralocorticoid
receptor antagonist, should be based on the result of AVS.
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We heartily thank Dr Tanemoto1 for the interest in our
article.2 We agree that traditional planar adrenal scinti-
graphy with NP-59 and dexamethasone suppression has
low sensitivity and specificity and cannot detect adenomas
o1 cm in diameter. Despite the high adrenal avidity of NP-
59, the computer hardware provides limited resolution and
does not allow detection of early adrenal activity.3
Single-photon emission computed tomography
(SPECT) provides spatial and quantitative data on
adrenocortical uptake and allows detection of smaller
lesions.4,5 In NP-59 SPECT, the hallmark of diagnosis is
early visualization before the fifth post-injection day.4 The
unilateral uptake signifies either frequent unilateral
adrenal adenoma, or rare unilateral adrenal hyperplasia,
both of which are surgically curable.6 SPECT/CT, which
uses an integrated dual-head gamma camera and a CT
scanner, provides functional and anatomical imaging in
one session, allows accurate localization of tumors, and
enhances the accuracy of SPECT, all of which may affect
clinical decision making.7 Higher levels of sensitivity,
specificity, positive predictive value, and negative predic-
tive value can be attained by performing SPECT/CT with
high-end CT.8
In our case, CT alone provided no evidence of a lesion,
and traditional planar NP-59 scintigraphy alone indicated
no uptake of radioactivity. However, radioactivity was
evident after SPECT imaging, and this was localized by
SPECT/CT. We did not use adrenal venous sampling
because this method is invasive, is associated with
various risks (even when performed by an experienced
expert), and because of difficulty in approaching the right
adrenal vein.9
By performing NP-59 SPECT/CT, we identified a
cortical micronodule that was 815 lm in diameter, the
smallest adenoma identified in a pathological examination
at present. NP-59 SPECT/CT is a significant technical
innovation that provides a noninvasive and promising
alternative for the diagnosis of subtle primary hyperaldos-
teronism when there is a high clinical suspicion despite a
negative confirmation test and negative CT scan.
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